Compare Amylx Pharmaceuticals Inc (AMLX) vs Philip Morris International Inc. (PM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Philip Morris International Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Philip Morris International Inc. trades at $181.83 (market cap $283.07B). The key difference: Philip Morris International Inc. is far larger — about 143× Amylx Pharmaceuticals Inc's market cap, and Philip Morris International Inc. pays a 3.24% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | PM | |
|---|---|---|
Market Cap | $1.98B | $283.07B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $191.86 |
52-Week Low | $7.64 | $144.33 |
Enterprise Value | $1.70B | $329.56B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Philip Morris International (PM) trades at $181.62, up 0.25% today, near the analyst consensus price target of $194. The stock shows a bullish technical trend with support at $179 and resistance at $185. Recent Q1 2026 earnings beat expectations at $1.96 EPS versus $1.86, though Q4 2025 missed. Revenue grew to $40.65B in 2025 with a strong net margin of 26.74%. The company announced a $1.47 dividend payable July 20, 2026, but cut its 2026 profit forecast due to a $500M impairment and cost pressures.
Outlook remains positive with 68% analyst buy ratings, but risks include rising illicit cigarette trade in Europe, currency volatility, and consumer spending constraints. The stock offers value with a P/E of 25.57 and stable cash flows, though high debt levels and regulatory challenges require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
